Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly

Journal of Virology

Volumn 88, Issue 3, 2014, Pages 1433-1446

  Hueging, Kathrin ^a   Doepke, Mandy ^a   Vieyres, Gabrielle ^a   Bankwitz, Dorothea ^a   Frentzen, Anne ^a   Doerrbecker, Juliane ^a   Gumz, Frauke ^a,d   Haid, Sibylle ^a   Wölk, Benno ^b   Kaderali, Lars ^c   Pietschmann, Thomas ^a  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C1; APOLIPOPROTEIN E; CORE PROTEIN; MICRORNA 122; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; VIRUS RNA;

ARTICLE; CELL CULTURE; CELL TRANSFER; CONTROLLED STUDY; EMBRYO; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; RNA REPLICATION; VIRAL TROPISM; VIRION; VIROGENESIS; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS ENVELOPE; VIRUS GENOME; VIRUS PARTICLE; VIRUS RELEASE;

APOLIPOPROTEINS E; CELL LINE, TUMOR; HEPACIVIRUS; HEPATITIS C; HUMANS; VIRAL CORE PROTEINS; VIRAL TROPISM; VIRION; VIRUS ASSEMBLY;

EID: 84892473356     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01815-13     Document Type: Article

References (74)

1. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17:107-115. http://dx.doi.org/10.1111/j.1469-0691.2010 .03432.x.
2. Delang L, Neyts J, Vliegen I, Abrignani S, Neddermann P, De Francesco R. 2013. Hepatitis C virus-specific directly acting antiviral drugs. Curr. Top. Microbiol. Immunol. 369:289-320. http://dx.doi.org/10.1007/978-3-642-27340-7_12.
3. Seeff LB. 2002. Natural history of chronic hepatitis C. Hepatology 36:S35-S46. http://dx.doi.org/10.1002/hep.1840360706.
4. Yamane D, McGivern DR, Masaki T, Lemon SM. 2013. Liver injury and disease pathogenesis in chronic hepatitis C. Curr. Top. Microbiol. Immunol. 369:263-288. http://dx.doi.org/10.1007/978-3-642-27340-7_11.
5. Weissenborn K, Tryc AB, Heeren M, Worthmann H, Pflugrad H, Berding G, Bokemeyer M, Tillmann HL, Goldbecker A. 2009. Hepatitis C virus infection and the brain. Metab. Brain Dis. 24:197-210. http://dx .doi.org/10.1007/s11011-008-9130-5.
6. Zignego AL, Giannini C, Monti M, Gragnani L. 2007. Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig. Liver Dis. 39(Suppl 1):S38-S45. http://dx.doi.org/10.1016/S1590-8658(07)80009-0.
7. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882-886. http://dx.doi.org/10.1038/nature07684.
8. Zeisel MB, Felmlee DJ, Baumert TF. 2013. Hepatitis C virus entry. Curr. Top. Microbiol. Immunol. 369:87-112. http://dx.doi.org/10.1007/978-3-642-27340-7_4.
9. Haid S, Grethe C, Dill MT, Heim M, Kaderali L, Pietschmann T. Isolate-dependent use of Claudins for cell entry by hepatitisCvirus. Hepatology, in press. http://dx.doi.org/10.1002/hep.26567.
10. Meertens L, Bertaux C, Cukierman L, Cormier E, Lavillette D, Cosset FL, Dragic T. 2008. The tight junction proteins claudin-1,-6, and-9 are entry cofactors for hepatitis C virus. J. Virol. 82:3555-3560. http://dx.doi .org/10.1128/JVI.01977-07.
11. Zheng A, Yuan F, Li Y, Zhu F, Hou P, Li J, Song X, Ding M, Deng H. 2007. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J. Virol. 81:12465-12471. http://dx.doi.org/10.1128/JVI .01457-07.
12. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, von Weizsacker F, Blum HE, Baumert TF. 2003. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278:41003-41012. http://dx.doi.org/10.1074/jbc.M302267200.
13. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R. 2006. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 80:5308-5320. http://dx.doi.org/10.1128/JVI.02460-05.
14. Martin DN, Uprichard SL. 2013. Identification of transferrin receptor 1 as a hepatitisCvirus entry factor. Proc. Natl. Acad. Sci. U.S.A. 110:10777-10782. http://dx.doi.org/10.1073/pnas.1301764110.
15. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. 2011. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 17:589-595. http://dx.doi.org/10.1038/nm.2341.
16. Sainz B, Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. 2012. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 18:281-285. http://dx .doi.org/10.1038/nm.2581.
17. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. 1999. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. U.S.A. 96:12766-12771. http://dx.doi.org/10.1073/pnas.96.22.12766.
18. Albecka A, Belouzard S, Op de Beeck A, Descamps V, Goueslain L, Bertrand-Michel J, Terce F, Duverlie G, Rouille Y, Dubuisson J. 2012. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 55:998-1007. http://dx.doi.org/10.1002/hep.25501.
19. Owen DM, Huang H, Ye J, Gale M, Jr. 2009. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with lowdensity lipoprotein receptor. Virology 394:99-108. http://dx.doi.org/10 .1016/j.virol.2009.08.037.
20. Steinmann E, Pietschmann T. 2013. Cell culture systems for hepatitis C virus. Curr. Top. Microbiol. Immunol. 369:17-48. http://dx.doi.org/10 .1007/978-3-642-27340-7_2.
21. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. 2005. Modu-lation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309:1577-1581. http://dx.doi.org/10.1126/science.1113329.
22. Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM. 2008. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J. Virol. 82:8215-8223. http://dx.doi.org/10 .1128/JVI.02575-07.
23. Frentzen A, Kusuma A, Guerlevik E, Hueging K, Knocke S, Ginkel C, Brown RJ, Heim M, Dill MT, Kroger A, Kalinke U, Kaderali L, Kuehnel F, Pietschmann T. Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells. Hepatology, in press. http://dx.doi.org/10.1002/hep.26626.
24. Lin LT, Noyce RS, Pham TN, Wilson JA, Sisson GR, Michalak TI, Mossman KL, Richardson CD. 2010. Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. J. Virol. 84:9170-9180. http://dx.doi.org/10.1128/JVI.00559-10.
25. Merz A, Long G, Hiet MS, Brugger B, Chlanda P, Andre P, Wieland F, Krijnse-Locker J, Bartenschlager R. 2011. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J. Biol. Chem. 286:3018-3032. http://dx.doi.org/10.1074/jbc .M110.175018.
26. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. 2006. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J. Virol. 80:2418-2428. http://dx.doi.org/10.1128/JVI.80.5.2418-2428.2006.
27. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. 1992. Association of hepatitisCvirus in human sera with beta-lipoprotein. Med. Microbiol. Immunol. Berl. 181:293-300. http://dx.doi.org/10.1007/BF00198849.
28. Catanese MT, Uryu K, Kopp M, Edwards TJ, Andrus L, Rice WJ, Silvestry M, Kuhn RJ, Rice CM. 2013. Ultrastructural analysis of hepatitis C virus particles. Proc. Natl. Acad. Sci. U.S.A. 110:9505-9510. http://dx .doi.org/10.1073/pnas.1307527110.
29. Kono Y, Hayashida K, Tanaka H, Ishibashi H, Harada M. 2003. Highdensity lipoprotein binding rate differs greatly between genotypes 1b and 2a/2b of hepatitis C virus. J. Med. Virol. 70:42-48. http://dx.doi.org/10 .1002/jmv.10372.
30. Lindenbach BD. 2013. Virion assembly and release. Curr. Top. Microbiol. Immunol. 369:199-218. http://dx.doi.org/10.1007/978-3-642-27340-7_8.
31. Chang KS, Jiang J, Cai Z, Luo G. 2007. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J. Virol. 81:13783-13793. http://dx.doi.org/10.1128/JVI.01091-07.
32. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. 2008. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 82:2120-2129. http://dx.doi.org/10.1128/JVI .02053-07.
33. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Jr., Ye J. 2007. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. U.S.A. 104:5848-5853. http://dx.doi.org/10.1073/pnas.0700760104.
34. Meunier JC, Russell RS, Engle RE, Faulk KN, Purcell RH, Emerson SU. 2008. Apolipoprotein c1 association with hepatitis C virus. J. Virol. 82: 9647-9656. http://dx.doi.org/10.1128/JVI.00914-08.
35. Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, Yarmush ML. 2008. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 47: 1437-1445. http://dx.doi.org/10.1002/hep.22197.
36. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U.S.A. 103:7408-7413. http://dx.doi.org/10.1073/pnas.0504877103.
37. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Buhler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R. 2011. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 9:32-45. http://dx.doi.org/10.1016/j.chom.2010 .12.002.
38. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817. http://dx.doi.org/10.1053/j.gastro.2003.09.023.
39. Long G, Hiet MS, Windisch MP, Lee JY, Lohmann V, Bartenschlager R. 2011. Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Gastroenterology 141:1057-1066. http://dx.doi.org/10.1053/j .gastro.2011.06.010.
40. Narbus CM, Israelow B, Sourisseau M, Michta ML, Hopcraft SE, Zeiner GM, Evans MJ. 2011. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J. Virol. 85:12087-12092. http://dx.doi.org/10.1128/JVI.05843-11.
41. Steinmann E, Brohm C, Kallis S, Bartenschlager R, Pietschmann T. 2008. Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. J. Virol. 82:7034-7046. http://dx.doi.org/10 .1128/JVI.00118-08.
42. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. 1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72:8463-8471.
43. Kalajzic I, Stover ML, Liu P, Kalajzic Z, Rowe DW, Lichtler AC. 2001. Use of VSV-G pseudotyped retroviral vectors to target murine osteoprogenitor cells. Virology 284:37-45. http://dx.doi.org/10.1006/viro.2001 .0903.
44. Pham HM, Arganaraz ER, Groschel B, Trono D, Lama J. 2004. Lentiviral vectors interfering with virus-induced CD4 down-modulation potently block human immunodeficiency virus type 1 replication in primary lymphocytes. J. Virol. 78:13072-13081. http://dx.doi.org/10.1128/JVI.78 .23.13072-13081.2004.
45. Haid S, Pietschmann T, Pecheur EI. 2009. Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition and density of virus particles. J. Biol. Chem. 284:17657-17667. http://dx.doi.org/10.1074/jbc.M109.014647.
46. van den Hoff MJ, Labruyere WT, Moorman AF, Lamers WH. 1990. The osmolarity of the electroporation medium affects the transient expression of genes. Nucleic Acids Res. 18:6464. http://dx.doi.org/10.1093/nar/18.21 .6464.
47. Vieyres G, Pietschmann T. 2013. Entry and replication of recombinant hepatitis C viruses in cell culture. Methods 59:233-248. http://dx.doi.org/10.1016/j.ymeth.2012.09.005.
48. Kärber G. 1931. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Archiv. Exp. Pathol. Pharmakol. 162:480-487. http://dx .doi.org/10.1007/BF01863914.
49. Spearman C. 1908. The method of "right and wrong cases" ("constant stimuli") without Gauss's formulae. Br. J. Psychol. 2:227-242.
50. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M. 2012. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 109:6205-6210. http://dx.doi.org/10.1073/pnas .1114927109.
51. Gentzsch J, Brohm C, Steinmann E, Friesland M, Menzel N, Vieyres G, Perin PM, Frentzen A, Kaderali L, Pietschmann T. 2013. Hepatitis C virus p7 is critical for capsid assembly and envelopment. PLoS Pathog. 9:e1003355. http://dx.doi.org/10.1371/journal.ppat.1003355.
52. Menzel N, Fischl W, Hueging K, Bankwitz D, Frentzen A, Haid S, Gentzsch J, Kaderali L, Bartenschlager R, Pietschmann T. 2012. MAPkinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles. PLoS Pathog. 8:e1002829. http://dx.doi.org/10.1371/journal.ppat.1002829.
53. Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T. 2007. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog. 3:e103. http://dx.doi.org/10 .1371/journal.ppat.0030103.
54. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM.2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. http://dx.doi.org/10.1126/science.1114016.
55. Moradpour D, Englert C, Wakita T, Wands JR. 1996. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 222:51-63. http://dx.doi.org/10.1006/viro.1996.0397.
56. Hope RG, McLauchlan J. 2000. Sequence motifs required for lipid droplet association and protein stability are unique to the hepatitis C virus core protein. J. Gen. Virol. 81:1913-1925.
57. Ciesek S, Westhaus S, Wicht M, Wappler I, Henschen S, Sarrazin C, Hamdi N, Abdelaziz AI, Strassburg CP, Wedemeyer H, Manns MP, Pietschmann T, von Hahn T. 2011. Impact of intra-and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles. J. Virol. 85:7613-7621. http://dx.doi.org/10.1128/JVI .00212-11.
58. Jones CT, Catanese MT, Law LM, Khetani SR, Syder AJ, Ploss A, Oh TS, Schoggins JW, MacDonald MR, Bhatia SN, Rice CM. 2010. Realtime imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat. Biotechnol. 28:167-171. http://dx.doi.org/10.1038/nbt.1604.
59. Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, Chow S, Chang J, Baumert TF, McKeating JA, McKelvy J, Wong-Staal F. 2011. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J. Hepatol. 54:48-55. http://dx.doi.org/10.1016/j.jhep.2010.06 .024.
60. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K. 2007. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. 9:1089-1097. http://dx.doi.org/10.1038/ncb1631.
61. Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris HJ, Schwarz A, Desombere I, Roels GL, Balfe P, McKeating JA. 2008. HepatitisCvirus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47:17-24. http://dx.doi.org/10.1002/hep.21959.
62. Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, Angus AG, Keck ZY, Foung SK, Pietschmann T, Rice CM, Patel AH. 2009. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J. Gen. Virol. 90:48-58. http://dx.doi.org/10.1099/vir.0 .006700-0.
63. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:1167-1172. http://dx.doi.org/10.1038/nature04193.
64. Da Costa D, Turek M, Felmlee DJ, Girardi E, Pfeffer S, Long G, Bartenschlager R, Zeisel MB, Baumert TF. 2012. Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. J. Virol. 86:11919-11925. http://dx.doi.org/10.1128/JVI.01066-12.
65. Jiang J, Cun W, Wu X, Shi Q, Tang H, Luo G. 2012. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J. Virol. 86:7256-7267. http://dx.doi.org/10.1128/JVI.07222-11.
66. Jammart B, Michelet M, Pecheur EI, Parent R, Bartosch B, Zoulim F, Durantel D. 2013. Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells. J. Virol. 87:5065-5080. http://dx.doi .org/10.1128/JVI.01405-12.
67. Thomssen R, Bonk S, Thiele A. 1993. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med. Microbiol. Immunol. Berl. 182:329-334.
68. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA, Lanford RE, Feinstone SM, Major ME, Leroux-Roels G, Rice CM. 2006. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl. Acad. Sci. U.S.A. 103:3805-3809. http://dx.doi.org/10.1073/pnas.0511218103.
69. Podevin P, Carpentier A, Pene V, Aoudjehane L, Carriere M, Zaidi S, Hernandez C, Calle V, Meritet JF, Scatton O, Dreux M, Cosset FL, Wakita T, Bartenschlager R, Demignot S, Conti F, Rosenberg AR, Calmus Y. 2010. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology 139:1355-1364. http://dx.doi.org/10.1053/j.gastro.2010.06.058.
70. Roelandt P, Obeid S, Paeshuyse J, Vanhove J, Van Lommel A, Nahmias Y, Nevens F, Neyts J, Verfaillie CM. 2012. Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus. J. Hepatol. 57:246-251. http://dx.doi.org/10.1016/j.jhep.2012.03.030.
71. Schwartz RE, Trehan K, Andrus L, Sheahan TP, Ploss A, Duncan SA, Rice CM, Bhatia SN. 2012. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc. Natl. Acad. Sci. U.S.A. 109:2544-2548. http://dx.doi.org/10.1073/pnas.1121400109.
72. Wu X, Robotham JM, Lee E, Dalton S, Kneteman NM, Gilbert DM, Tang H. 2012. Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog. 8:e1002617. http://dx.doi.org/10.1371/journal .ppat.1002617.
73. Coller KE, Heaton NS, Berger KL, Cooper JD, Saunders JL, Randall G. 2012. Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog. 8:e1002466. http://dx.doi.org/10.1371/journal.ppat.1002466.
74. Counihan NA, Rawlinson SM, Lindenbach BD. 2011. Trafficking of hepatitis C virus core protein during virus particle assembly. PLoS Pathog. 7:e1002302. http://dx.doi.org/10.1371/journal.ppat.1002302.